BRPI0915627A2 - compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos - Google Patents

compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos

Info

Publication number
BRPI0915627A2
BRPI0915627A2 BRPI0915627A BRPI0915627A BRPI0915627A2 BR PI0915627 A2 BRPI0915627 A2 BR PI0915627A2 BR PI0915627 A BRPI0915627 A BR PI0915627A BR PI0915627 A BRPI0915627 A BR PI0915627A BR PI0915627 A2 BRPI0915627 A2 BR PI0915627A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions containing
indole derivatives
indole
derivatives
Prior art date
Application number
BRPI0915627A
Other languages
English (en)
Inventor
Andrew Mccreary
Benaïssa Boubia
Bernard Johannes Van Vliet
Jacobus Antonius Joseph Den Hartog
Maria Johanna Petronella Van Dongen
Mireille Tallandier
Olivia Poupardin-Olivier
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Publication of BRPI0915627A2 publication Critical patent/BRPI0915627A2/pt
Publication of BRPI0915627A8 publication Critical patent/BRPI0915627A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0915627A 2008-07-10 2009-07-09 Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos BRPI0915627A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0854712A FR2933609B1 (fr) 2008-07-10 2008-07-10 Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
PCT/FR2009/051372 WO2010004221A2 (fr) 2008-07-10 2009-07-09 Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson

Publications (2)

Publication Number Publication Date
BRPI0915627A2 true BRPI0915627A2 (pt) 2016-07-26
BRPI0915627A8 BRPI0915627A8 (pt) 2017-05-16

Family

ID=40297845

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915627A BRPI0915627A8 (pt) 2008-07-10 2009-07-09 Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos

Country Status (27)

Country Link
US (1) US8575210B2 (pt)
EP (1) EP2300424B1 (pt)
JP (1) JP5396650B2 (pt)
KR (1) KR101606184B1 (pt)
CN (1) CN102112441B (pt)
AR (1) AR072718A1 (pt)
AT (1) ATE541831T1 (pt)
AU (1) AU2009269842B2 (pt)
BR (1) BRPI0915627A8 (pt)
CA (1) CA2730302C (pt)
CY (1) CY1112638T1 (pt)
DK (1) DK2300424T3 (pt)
EA (1) EA018079B1 (pt)
ES (1) ES2381180T3 (pt)
FR (1) FR2933609B1 (pt)
HR (1) HRP20120231T1 (pt)
IL (1) IL210386A (pt)
MX (1) MX2011000353A (pt)
MY (1) MY155959A (pt)
PL (1) PL2300424T3 (pt)
PT (1) PT2300424E (pt)
SA (1) SA109300453B1 (pt)
SI (1) SI2300424T1 (pt)
TW (1) TWI414289B (pt)
UA (1) UA102397C2 (pt)
WO (1) WO2010004221A2 (pt)
ZA (1) ZA201100041B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2955108B1 (fr) * 2010-01-08 2012-03-16 Fournier Lab Sa Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
KR101964889B1 (ko) 2017-11-17 2019-04-02 한국생명공학연구원 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
KR102059160B1 (ko) 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
US20220016073A1 (en) 2017-11-15 2022-01-20 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
KR20240020098A (ko) 2022-08-05 2024-02-14 엠테라파마 주식회사 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1373240B1 (en) * 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CN1886133B (zh) * 2003-12-04 2010-12-01 财团法人卫生研究院 吲哚化合物
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903106B1 (fr) 2006-07-03 2010-07-30 Sanofi Aventis Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2903105A1 (fr) 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CA2730302A1 (fr) 2010-01-14
CY1112638T1 (el) 2016-02-10
EA201170150A1 (ru) 2011-06-30
PT2300424E (pt) 2012-04-27
ES2381180T3 (es) 2012-05-23
CA2730302C (fr) 2017-03-07
WO2010004221A3 (fr) 2010-05-06
FR2933609A1 (fr) 2010-01-15
TWI414289B (zh) 2013-11-11
EA018079B1 (ru) 2013-05-30
HK1154852A1 (en) 2012-05-04
ATE541831T1 (de) 2012-02-15
KR20110110759A (ko) 2011-10-07
US8575210B2 (en) 2013-11-05
MX2011000353A (es) 2011-02-22
DK2300424T3 (da) 2012-04-16
SA109300453B1 (ar) 2013-05-18
ZA201100041B (en) 2012-03-28
HRP20120231T1 (hr) 2012-04-30
AU2009269842B2 (en) 2013-08-22
UA102397C2 (ru) 2013-07-10
FR2933609B1 (fr) 2010-08-27
JP5396650B2 (ja) 2014-01-22
BRPI0915627A8 (pt) 2017-05-16
EP2300424A2 (fr) 2011-03-30
SI2300424T1 (sl) 2012-04-30
IL210386A0 (en) 2011-03-31
PL2300424T3 (pl) 2012-06-29
KR101606184B1 (ko) 2016-03-24
AU2009269842A1 (en) 2010-01-14
MY155959A (en) 2015-12-31
EP2300424B1 (fr) 2012-01-18
US20110178150A1 (en) 2011-07-21
CN102112441B (zh) 2013-07-10
JP2011527326A (ja) 2011-10-27
IL210386A (en) 2015-09-24
TW201006468A (en) 2010-02-16
AR072718A1 (es) 2010-09-15
CN102112441A (zh) 2011-06-29
WO2010004221A2 (fr) 2010-01-14

Similar Documents

Publication Publication Date Title
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BR112013011949A2 (pt) "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis"
BRPI0906634A2 (pt) Drivados de indol 2-carboxamidas e de azaindol 2-carboxamidas substituídos por grupo sinanila, sua preparação e sua aplicação em terapêutica
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI1008878A2 (pt) compostos heterocíclicos, composições farmacêuticas contendo os mesmos, e seus usos como inibidores de transportador de glicina 1
CR10665A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0809346A2 (pt) Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BR112016000909A2 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0908175A2 (pt) derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
DK2282994T3 (da) 3-aminocarbazolforbindelse, farmaceutisk sammensætning indeholdende forbindelsen samt fremstillingsmetode derfor
BRPI0912356A2 (pt) compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
DK2242740T3 (da) SF5-derivater som par1-inhibitorer, deres fremstilling og anvendelse som lægemidler
BRPI1010239A2 (pt) endoglucanases aprimoradas, derivados e seus usos
BRPI0915627A2 (pt) compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos
CR10953A (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INVENTIVA (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]